Nuvectis Pharma, Inc. Common Stock
NVCTNuvectis Pharma, Inc. is a biopharmaceutical company focused on developing targeted medicines for the treatment of cancer and other serious conditions. The company specializes in leveraging precision medicine approaches to address unmet medical needs, particularly in the fields of oncology and rare diseases.
Company News
Nuvectis Pharma, a clinical-stage biopharmaceutical company, announced the pricing of its $13.5 million public offering of 2.7 million shares of common stock at $5 per share. The company plans to use the proceeds to advance the development of its drug candidates NXP800 and NXP900.
Nuvectis Pharma, Inc. reported its Q3 2024 financial results and provided updates on the development of its drug candidates NXP800 and NXP900. The company expects a clinical data update for NXP800 this month and has progressed the NXP900 Phase 1a study with no dose-limiting toxicities.
Nuvectis Pharma announced that the FDA granted Orphan Drug Designation for its drug candidate NXP800 to treat a subset of ovarian cancer with ARID1a deficiency. This designation provides financial incentives and potential marketing exclusivity if the drug is approved.
The average of price targets set by Wall Street analysts indicates a potential upside of 229.3% in Nuvectis Pharma (NVCT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Fort Lee, NJ, May 16, 2024 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced that Ron Bentsur, Chairman and Chief...
